NASDAQ:ANIK Anika Therapeutics (ANIK) Stock Price, News & Analysis $14.38 +0.29 (+2.06%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Anika Therapeutics Stock (NASDAQ:ANIK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Anika Therapeutics alerts:Sign Up Key Stats Today's Range$13.85▼$14.4350-Day Range$13.14▼$17.8252-Week Range$12.83▼$29.12Volume59,388 shsAverage Volume69,338 shsMarket Capitalization$203.85 millionP/E RatioN/ADividend YieldN/APrice Target$21.67Consensus RatingBuy Company OverviewAnika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Read More… Anika Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreANIK MarketRank™: Anika Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 211th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAnika Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Anika Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Anika Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.86% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Anika Therapeutics has recently decreased by 0.31%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.6 / 5Environmental Score-2.01 Percentage of Shares Shorted2.86% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Anika Therapeutics has recently decreased by 0.31%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.95 News SentimentAnika Therapeutics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Anika Therapeutics this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.86% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Anika Therapeutics' insider trading history. Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANIK Stock News HeadlinesRetractable Technologies (NYSE:RVP) versus Anika Therapeutics (NASDAQ:ANIK) Critical ComparisonApril 21, 2025 | americanbankingnews.comAnika Therapeutics (NASDAQ:ANIK) Earns Buy Rating from Analysts at B. RileyApril 20, 2025 | americanbankingnews.comReal Americans Don’t Wait on Wall Street’s Next MoveWhat's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.April 25, 2025 | Premier Gold Co (Ad)Anika Therapeutics (ANIK) Receives 'Buy' Rating with $21 Target from B. ...April 17, 2025 | gurufocus.comAnika Therapeutics (ANIK) Receives 'Buy' Rating with $21 Target from B. ...April 17, 2025 | gurufocus.comAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 7, 2025 | globenewswire.comAre Options Traders Betting on a Big Move in Anika Therapeutics (ANIK) Stock?April 3, 2025 | msn.comAnika Therapeutics Full Year 2024 Earnings: Misses ExpectationsMarch 14, 2025 | ca.finance.yahoo.comSee More Headlines ANIK Stock Analysis - Frequently Asked Questions How have ANIK shares performed this year? Anika Therapeutics' stock was trading at $16.46 at the beginning of the year. Since then, ANIK shares have decreased by 12.6% and is now trading at $14.38. View the best growth stocks for 2025 here. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its quarterly earnings results on Wednesday, March, 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by $0.13. The biotechnology company earned $30.60 million during the quarter, compared to the consensus estimate of $29 million. Anika Therapeutics had a negative net margin of 59.40% and a negative trailing twelve-month return on equity of 2.22%. Read the conference call transcript. Who are Anika Therapeutics' major shareholders? Top institutional investors of Anika Therapeutics include Allspring Global Investments Holdings LLC (0.28%), Rhumbline Advisers (0.15%) and GAMMA Investing LLC (0.05%). View institutional ownership trends. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anika Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Advanced Micro Devices (AMD), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings3/12/2025Today4/25/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:ANIK CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees300Year Founded1992Price Target and Rating Average Stock Price Target$21.67 High Stock Price Target$24.00 Low Stock Price Target$20.00 Potential Upside/Downside+50.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,670,000.00 Net Margins-59.40% Pretax Margin-57.58% Return on Equity-2.22% Return on Assets-1.75% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio3.78 Sales & Book Value Annual Sales$119.91 million Price / Sales1.70 Cash Flow$4.07 per share Price / Cash Flow3.53 Book Value$14.50 per share Price / Book0.99Miscellaneous Outstanding Shares14,176,000Free Float13,495,000Market Cap$203.85 million OptionableOptionable Beta0.82 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:ANIK) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.